• Latest Posts
In Depth 30 Nov 2023

Could an Alzheimer’s vaccine make treatment more affordable?

Opinion 29 Nov 2023

Redefining drug development: the trailblazing evolution of the pharmaceutical industry

Five companies shaping Texas’ growing biotech hubs

In Depth 27 Nov 2023

How are R&D Tax Incentives shaping Australia’s biotech future?

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA 

Podcast 24 Nov 2023

Company exits stealth to launch molecular gates

ADVERTISEMENT
In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

M&As: what’s up with the ADC buying spree?

With $700 million Q3 rise, U.K. biotech spearheads European recovery

Podcast 17 Nov 2023

How can life-saving vaccines be more affordable?

ADVERTISEMENT